OxThera AB is being granted US patent for Oxalobactersecretagogues
OxThera AB, a privately-held Stockholm-based biopharmaceutical company, today announced a granted US patent on Oxalobacter formigenes secretagogues. Oxabact® , a formulation of highly concentrated lyophilized Oxalobacter formigenes, is being developed by OxThera AB as a potential treatment for patients with primary hyperoxaluria (PH). Oxabact® is designed to increase the intestinal secretion of oxalate from plasma and thereby decrease and prevent oxalate crystal accumulation and kidney deterioration. Oxalobacter formigenes produces specific secretagogues that enhance active